ReviewCancers2024

Circulating Tumor DNA as a Complementary Prognostic Biomarker during CAR-T Therapy in B-Cell Non-Hodgkin Lymphomas.

Sarah Monick et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.